Preoperative ROS1-TKI Therapy for ROS1 Fusion-Positive Locally Advanced Lung Adenocarcinoma

This multicenter retrospective study evaluates preoperative ROS1-TKI therapy in patients with ROS1 fusion-positive locally advanced lung adenocarcinoma. Patients who received ROS1-TKI therapy before surgical resection were retrospectively identified from four tertiary hospitals in China. The study describes clinicopathological characteristics, radiographic response, treatment-related adverse events, surgical outcomes, pathological response, and follow-up outcomes.

NCT Number	NCT07700836
Lead Sponsor	Peking University Cancer Hospital & Institute
Conditions	ROS1 Fusion-Positive Lung Adenocarcinoma
Enrollment	12 participants
Start Date	2021-07-01
Primary Completion	2025-09-03 (estimated)
Study Completion	2025-11-17 (estimated)
Updated on ClinicalTrials.gov	2026-07-15